Cohort 1 LITESPARK-003: belzutifan + cabozantinib 1L treatment for advanced RCC

David A. Braun, MD, PhD, discusses the preliminary analysis of belzutifan + cabozantinib in ccRCCПодробнее

Highlights on belzutifan in previously treated advanced clear cell RCC: The LITESPARK-005 studyПодробнее

Practice Update: Updated Results of Belzutifan for Advanced RCCПодробнее

Cabozantinib Plus Atezolizumab as First-Line Therapy for Advanced Renal Cell CarcinomaПодробнее

Belzutifan - Welireg - In a nutshell.Подробнее

LITESPARK-004: 36 month follow-up of belzutifan in Von Hippel-Lindau syndromeПодробнее

RCC Update from ESMO 2023Подробнее

Cohort 1 of LITESPARK-003Подробнее

Eleni Efstathiou, MD, PhD, regarding the preliminary analysis of belzutifan & cabozantinib in ccRCCПодробнее

Assessing the real-world outcomes and safety of belzutifan in patients with VHL associated tumorsПодробнее

Phase Ib/II trial of 177Lu-girentuximab with cabozantinib and nivolumab in clear cell RCCПодробнее

Welireg Wins FDA Approval for Advanced Renal Cell Carcinoma, the Second for the Merck DrugПодробнее

Cabozantinib Plus Atezolizumab for Non-Clear Cell Renal Cell CarcinomaПодробнее

Unanswered questions of interest from the LITESPARK-004 trialПодробнее

What is the best second-line treatment of advanced renal cell carcinoma (RCC)?Подробнее

Phase III METEOR trial: cabozantinib vs everolimus for advanced clear cell renal cell carcinomaПодробнее

Promising results of cabozantinib plus nivolumab in non-clear cell RCCПодробнее

Dr. Pal on the Safety Profile of Cabozantinib/Atezolizumab in Advanced RCCПодробнее

ASCO GU23 CheckMate-9ER Biomarker Analysis: Toni Choueiri, MD | Dana-Farber Cancer InstituteПодробнее